EA201891687A1 - Новые замещённые производные цианиндолина в качестве nik- ингибиторов - Google Patents

Новые замещённые производные цианиндолина в качестве nik- ингибиторов

Info

Publication number
EA201891687A1
EA201891687A1 EA201891687A EA201891687A EA201891687A1 EA 201891687 A1 EA201891687 A1 EA 201891687A1 EA 201891687 A EA201891687 A EA 201891687A EA 201891687 A EA201891687 A EA 201891687A EA 201891687 A1 EA201891687 A1 EA 201891687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nik
inhibitors
diseases
cyanindoline
derivatives
Prior art date
Application number
EA201891687A
Other languages
English (en)
Other versions
EA201891687A9 (ru
EA037358B1 (ru
Inventor
Ян Стэнсфилд
Оливье Алексис Жорж Керолль
Виржини Софи Понселе
Герхард Макс Гросс
Эдгар Якоби
Льевен Меерпоель
Януш Йозеф Кулаговский
Калум Маклеод
Самюэль Эдвард Манн
Саймон Ричард Грин
Джордж Хинд
Original Assignee
Янссен Фармасьютика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармасьютика Нв filed Critical Янссен Фармасьютика Нв
Priority claimed from PCT/EP2017/051150 external-priority patent/WO2017125530A1/en
Publication of EA201891687A1 publication Critical patent/EA201891687A1/ru
Publication of EA201891687A9 publication Critical patent/EA201891687A9/ru
Publication of EA037358B1 publication Critical patent/EA037358B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим агентам, пригодным для лечения и/или профилактики млекопитающего, и, в частности, к ингибиторам индуцируемой сигнальным путём NF-κВ киназы (NIK - известной также как MAP3K14), пригодным для лечения заболеваний, таких как рак, воспалительные заболевания, метаболические расстройства и аутоиммунные заболевания. Данное изобретение предусматривает также фармацевтические композиции, содержащие такие соединения, и применение таких соединений или фармацевтических композиций для профилактики или лечения заболеваний, таких как рак, воспалительные заболевания, метаболические расстройства, включая ожирение и диабет, и аутоиммунные заболевания.
EA201891687A 2016-03-10 2017-01-20 Новые замещённые производные цианиндолина в качестве nik-ингибиторов EA037358B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16159651 2016-03-10
PCT/EP2017/051150 WO2017125530A1 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as nik inhibitors

Publications (3)

Publication Number Publication Date
EA201891687A1 true EA201891687A1 (ru) 2019-06-28
EA201891687A9 EA201891687A9 (ru) 2020-01-15
EA037358B1 EA037358B1 (ru) 2021-03-17

Family

ID=55521629

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891687A EA037358B1 (ru) 2016-03-10 2017-01-20 Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Country Status (1)

Country Link
EA (1) EA037358B1 (ru)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2728767A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
EA201891687A9 (ru) 2020-01-15
EA037358B1 (ru) 2021-03-17

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201792047A1 (ru) Новые соединения
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201790904A1 (ru) Новые производные пиразола в качестве ингибиторов nik
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EA201790908A1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
EA201790688A1 (ru) Новые соединения в качестве ингибиторов nik
EA201690657A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
EA201690645A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201692470A1 (ru) Фармацевтические комбинации
TW201613577A (en) Pharmaceutical combinations
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
EA201891687A1 (ru) Новые замещённые производные цианиндолина в качестве nik- ингибиторов
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
EA202090969A1 (ru) Третичные спирты в качестве ингибиторов pi3k-
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена